Alpha- Antitrypsin Deficiency Treatment market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Alpha- Antitrypsin Deficiency Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Alpha- Antitrypsin Deficiency Treatment market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Segment by Application
Clinic
Hospital
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.